As of 2025-04-18, the EV/EBITDA ratio of Chinook Therapeutics Inc (KDNY) is -11.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KDNY's latest enterprise value is 2,773.05 mil USD. KDNY's TTM EBITDA according to its financial statements is -233.23 mil USD. Dividing these 2 quantities gives us the above KDNY EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.0x - 10.9x | 9.8x |
| Forward P/E multiples | 15.3x - 30.4x | 19.7x |
| Fair Price | (47.93) - (33.70) | (46.14) |
| Upside | -218.7% - -183.4% | -214.2% |
| Date | EV/EBITDA |